Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03693105 · ClinicalTrials.gov registry record · Phase 2
The Effects of SAINT® Neuromodulation System on Explicit and Implicit Suicidal Cognition
A Phase 2 study, sponsored by Magnus Medical.
- Terminated
- Registry status
- Phase 2
- Development phase
- 2
- Enrollment target
NCT03693105 is a Phase 2 study that was terminated before completion, run by Magnus Medical. The registered enrollment target is 2 participants.
The verdict
NCT03693105, a Phase 2 study, was terminated before completion, sponsored by Magnus Medical.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 2 participants
- Enrollment target
Study Summary
This multi-site, double-blind, randomized, sham-controlled mechanistic trial aims to test the effects of Magnus Neuromodulation System (MNS) with Stanford Accelerated Intermittent Neuromodulation Therapy (SAINT®) Technology on the neural circuitry of suicidal cognitions in psychiatrically hospitalized patients with Major Depressive Disorder (MDD) and active suicidal ideation (SI). This will be accomplished by applying the MNS with SAINT to a customized target within the left dorsolateral prefrontal cortex (L-DLPFC) identified with fMRI for five consecutive days and measuring resting-state functional connectivity (RS FC) between the subgenual anterior cingulate cortex (sgACC) and the default mode network (DMN) at baseline and immediate-post visit. The relationship between changes in RS FC and changes in both Explicit and Implicit Suicidal Cognitions (ESC and ISC, respectively) will be determined. This study will also determine the relationship between changes in RS FC in neural networks underlying mediators of suicidal cognitions and changes in such mediators with active versus sham SAINT.
Interventions
- DEVICE Sham SAINT Stimulation
- DEVICE Active SAINT Stimulation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2024-06-30 |
| Est. Completion | 2025-03-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03693105
The ClinicalTrials.gov registry entry for NCT03693105 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Magnus Medical, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Sham SAINT Stimulation is the first listed.
NCT03693105 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03693105 about?
NCT03693105 is a clinical study titled "The Effects of SAINT® Neuromodulation System on Explicit and Implicit Suicidal Cognition". This multi-site, double-blind, randomized, sham-controlled mechanistic trial aims to test the effects of Magnus Neuromodulation System (MNS) with Stanford Accelerated Intermittent Neuromodulation Therapy (SAINT®) Technology on the neural circuitry of suicidal cognitions in psychiatrically hospitaliz...
What is the current status of trial NCT03693105?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 2 participants. The study started on 2024-06-30. Estimated completion is 2025-03-06.
What interventions are being tested in trial NCT03693105?
The interventions under investigation include: Sham SAINT Stimulation (DEVICE), Active SAINT Stimulation (DEVICE).
Who is sponsoring clinical trial NCT03693105?
This trial is sponsored by Magnus Medical, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.